Abstract | BACKGROUND: METHODS: RESULTS: A total of 16 assessable patients were enrolled. No complete or partial responses were observed. Two patients with epithelioid histology had minor responses. Three other patients remained on study with stable disease for 9, 9, and 48 months. The median time to progression was 3 months. The overall median survival time was 7 months (95% confidence interval: 3.2-16.2 months) and the one-year survival was 31% (95% confidence interval: 15%-65%). Three patients (19%) had grade 2 stomatitis, eight (50%) had grade 3, and one (6%) had grade 4. CONCLUSIONS:
|
Authors | Lee M Krug, Robert T Heelan, Mark G Kris, Ennapadam Venkatraman, F M Sirotnak |
Journal | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
(J Thorac Oncol)
Vol. 2
Issue 4
Pg. 317-20
(Apr 2007)
ISSN: 1556-1380 [Electronic] United States |
PMID | 17409804
(Publication Type: Clinical Trial, Phase II, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- 10-propargyl-10-deazaaminopterin
- Aminopterin
|
Topics |
- Aged
- Aged, 80 and over
- Aminopterin
(administration & dosage, analogs & derivatives)
- Confidence Intervals
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Female
- Humans
- Male
- Maximum Tolerated Dose
- Mesothelioma
(drug therapy, mortality, pathology)
- Middle Aged
- Neoplasm Staging
- Palliative Care
- Pleural Neoplasms
(drug therapy, mortality, pathology)
- Probability
- Prognosis
- Risk Assessment
- Survival Analysis
- Terminally Ill
|